The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
Xie, P., Streu, C., Qin, J., Bregman, H., Pagano, N., Meggers, E., Marmorstein, R.(2009) Biochemistry 48: 5187-5198
- PubMed: 19371126 
- DOI: 10.1021/bi802067u
- Primary Citation of Related Structures:  
3Q4C - PubMed Abstract: 
Substitution mutations in the BRAF serine/threonine kinase are found in a variety of human cancers. Such mutations occur in approximately 70% of human malignant melanomas, and a single hyperactivating V600E mutation is found in the activation segment of the kinase domain and accounts for more than 90% of these mutations ...